Renovacor Announces Appointment of Kumar Dhanasekharan, Ph.D., as Senior Vice President of Technical Operations



Dr Dhanasekharan joins Renovacor with extensive experience in overseeing development, manufacturing and supply operations of biologics, including AAV gene therapies

PHILADELPHIA, October 04, 2021– (BUSINESS WIRE) – Renovacor, Inc. (NYSE: RCOR), a biotechnology company developing adeno-associated virus (AAV) gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 genetic variants, today announced the appointment of Kumar Dhanasekharan, Ph.D., as Senior Vice President of Technical Operations.

“With the appointment of Kumar, we have added another innovative industry expert to Renovacor’s diverse and growing management team,” said Magdalene Cook, MD, CEO of Renovacor. “Kumar is the ideal solution for the business, as he has extensive experience in creating technical operations functions and overseeing CMC’s strategy for early stage AAV gene therapy programs. His experience will be invaluable as we move towards the planned IND filing of REN-001 in the middle of next year. “

Dr Dhanasekharan added, “Renovacor is an exciting company with seasoned industry leaders and strong fundamental science that demonstrates the ability of REN-001 to improve heart function in several models of preclinical heart failure. I look forward to joining my new colleagues as we work to move REN forward. -001 and the rest of the pipeline. Our complementary skills will be very useful to us in the pursuit of our mission of meeting the unmet needs of patients with BAG3 associated diseases. “

Prior to joining Renovacor, Dr. Dhanasekharan was Vice President of Technical Operations at SwanBio Therapeutics. While at SwanBio Therapeutics, Dr. Dhanasekharan oversaw process development, analytical and formulation development, external manufacturing and supply operations for the company’s AAV gene therapy programs. In this role, Dr Dhanasekharan designed and implemented a Chemistry, Manufacturing and Controls (CMC) strategy that led to the development of a scalable, serum-free manufacturing platform and successful manufacturing to support a IND. Prior to SwanBio, Dr Dhanasekharan was Executive Director and Head of Technical Development and Technology Transfer at Amicus Therapeutics, where he helped design an AAV gene therapy manufacturing facility and set up a development organization and a laboratory operations team of over 30 scientists, as well as a senior level management team to move the company’s biologics to phase III and process validation and gene therapy programs AAV in phase I / II. Dr Dhanasekharan also previously served as Director and Head of Process and Analytics Development at Cook Pharmica (which has since been acquired by Catelant); Director / Principal, Process and Technology Development at Lonza (formerly Bend Research Inc.); and in positions of increasing responsibility at Sanofi Genzyme.

Dr Dhanasekharan holds a doctorate. in Food Science (Process Engineering Major) from Rutgers University and a BS in Chemical Engineering from Indian Institute of Technology, Chennai (Madras), India.

About Rénovacor

Renovacor is a preclinical stage gene therapy company developing a pipeline of innovative and proprietary AAV-based gene therapies for BAG3 diseases associated with gene mutations in areas with high unmet medical needs. The therapeutic orientation of Renovacor is initially focused on cardiovascular diseases, with a program of BAG3 Mutation-associated dilated cardiomyopathy (DCM). For more information, please visit No part of the Renovacor website is incorporated by reference or otherwise considered to be part of this press release.

Forward-looking statements

This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the expected development of Renovacor’s product candidates. These forward-looking statements are generally identified by the words “believe”, “plan”, “expect”, “anticipate”, “estimate”, “intend”, “the strategy”, “the future”, ” opportunity ”,“ plan, “may”, “should”, “will”, “would”, “will”, “will continue”, “will probably result” and similar expressions. Forward-looking statements are predictions, projections and other statements regarding future events that are based on current expectations and assumptions and, therefore, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements contained in this press release. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of Renovacor’s proxy circular / definitive disclosure statement dated August 4, 2021 and other documents filed by Renovacor from time to time with the Securities Exchange Commission. These documents identify and discuss important risks and uncertainties that could cause actual events and results to differ materially from those contained in forward-looking statements. Forward-looking statements speak only as of the date on which they are made. Readers are cautioned not to place undue reliance on forward-looking statements, and Renovacor assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. Renovacor gives no assurance that it will meet its expectations.

View the source version on


Investor contact:
John mullaly
LifeSci Advisors
[email protected]

Media contact:
Patrick bursey
LifeSci Communications
[email protected]

Source link


Leave A Reply